Literature DB >> 9577426

Neoadjuvant chemotherapy for high grade malignant fibrous histiocytoma of bone.

G Bacci1, P Picci, M Mercuri, F Bertoni, S Ferrari.   

Abstract

Between March 1983 and December 1994, 65 patients with malignant fibrous histiocytoma of bone in the extremities were treated with neoadjuvant chemotherapy administered according to four different regimens. A limb salvage was done in 58 patients (89%) and amputation in seven. The histologic response to preoperative chemotherapy was good (90% or more tumor necrosis) in 16 patients (25%) and poor in 49 (75%). At a median followup of 7 years (range, 2-13 years), 40 patients (69%) remained continuously free of disease and 20 patients experienced relapse (18 with metastases and two with local recurrences followed by metastases). The rate of disease free survival was significantly higher for patients who had a good response than for those who had a poor response (94% versus 61%), although no significant differences in histologic response and disease free survival were seen with the four different regimens. These results show that a high percentage of patients with malignant fibrous histiocytoma of the extremities can be cured with neoadjuvant chemotherapy and that for most of them it is possible to avoid amputation.

Entities:  

Mesh:

Year:  1998        PMID: 9577426

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  5 in total

1.  [Primary malignant bone tumors].

Authors:  R von Eisenhart-Rothe; A Toepfer; M Salzmann; J Schauwecker; H Gollwitzer; H Rechl
Journal:  Orthopade       Date:  2011-12       Impact factor: 1.087

2.  MFH of bone and osteosarcoma show similar survival and chemosensitivity.

Authors:  Dae-Geun Jeon; Won Seok Song; Chang-Bae Kong; Jung Ryul Kim; Soo-Yong Lee
Journal:  Clin Orthop Relat Res       Date:  2010-06-18       Impact factor: 4.176

3.  [Update and interpretation of 2021 National Comprehensive Cancer Network (NCCN) "Clinical Practice Guidelines for Bone Tumors"].

Authors:  Ming Ni
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-09-15

4.  Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study.

Authors:  Kjetil Berner; Tom Børge Johannesen; Kirsten Sundby Hall; Øyvind S Bruland
Journal:  J Bone Oncol       Date:  2018-11-20       Impact factor: 4.072

5.  Clinical characteristics and prognostic factors of malignant fibrous histiocytoma of bone: a SEER population-based study.

Authors:  Lin Qi; Chao Tu; Xiaolei Ren; Ruiqi Chen; Lu Wan; Chenghao Zhang; Zhihong Li
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.